Clinical Trial Update: Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating risedronate to prevent cancer treatment-induced bone loss in men with prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• risedronate (risedronate)

Snippet

Sponsor: CMX Research | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED